Next-Gen Continual Stimulation Therapy (STARI Trial)
Early mechanical ventilation support to improve lung, diaphragm, cardiac, and brain function
Clinical TrialActive
Key Facts
Indication
Early mechanical ventilation support to improve lung, diaphragm, cardiac, and brain function
Phase
Clinical Trial
Status
Active
Company
About Lungpacer Medical
Lungpacer Medical is a commercial-stage medical device innovator with a FDA PMA-approved product, the AeroPace System, for temporary transvenous diaphragm neurostimulation. The technology is clinically proven to accelerate weaning from mechanical ventilation, reduce ICU days, and lower risks of reintubation and tracheostomy in difficult-to-wean patients. With recent CMS NTAP approval enhancing reimbursement, the company is positioned to penetrate the large critical care ventilator weaning market while developing next-generation continual stimulation therapies.
View full company profile